Partnership

Stem Cell Research Institute and Neurotech Medical Partner to Utilize Umbilical Cord-Derived Stem Cell Culture Supernatant "Family Seijo®" for Neural Regeneration

Citation-Grade Primary-source linked Schema.org verified

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Jul 3, 2026 9:30 PM ・ Updated Jul 8, 2026 7:02 PM ・ 10 min read ・ Source: PR TIMES

Show contents

Stem Cell Research Institute and Neurotech Medical Partner to Utilize Umbilical Cord-Derived Stem Cell Culture Supernatant "Family Seijo®" for Neural Regeneration — Image: PR TIMES

Stem Cell Research Institute Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Takafumi Shimizu; hereinafter "Stem Cell Research Institute") and Neurotech Medical Co., Ltd. (Headquarters:

PRIMARY SOURCE Original source: https://prtimes.jp/main/html/rd/p/000000067.000026419.html Distributor: PR TIMES
Published: Jul 3, 2026

Stem Cell Research Institute Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Takafumi Shimizu; hereinafter "Stem Cell Research Institute") and Neurotech Medical Co., Ltd. (Headquarters: Joto-ku, Osaka; President: Nagatoshi Kihouin; hereinafter "Neurotech Medical") are pleased to announce that they will commence a partnership on July 3, 2026, for the utilization of umbilical cord-derived stem cell culture supernatant "Family Seijo®" in the field of neural regeneration.

Stem Cell Research Institute, a cell bank for perinatal tissues centered on umbilical cords and cord blood, boasts a 99% domestic market share. Neurotech Medical provides "Renewro®," which integrates the patented technology "Targeted Neural Regeneration TherapyTM" and the proprietary technology "Targeted RehabilitationTM." Through this partnership, the two companies will establish a new medical service provision system that leverages their respective expertise.

Overview of this Partnership

Based on the instructions of physicians at Neurotech Medical's partner clinics, Stem Cell Research Institute will undertake the manufacturing of the stem cell culture supernatant "Family Seijo®" from umbilical cord-derived stem cells stored at Stem Cell Research Institute.

Neurotech Medical provides "Renewro®," which combines the patented technology "Targeted Neural Regeneration TherapyTM" and the proprietary technology "Targeted RehabilitationTM." Through this partnership, physicians at the company's partner clinics will consider the use of "Family Seijo®" as one of the options for private medical services in the field of neural regeneration, depending on the patient's condition.

About Stem Cell Research Institute's "Family Seijo®"

This is a service that manufactures stem cell culture supernatant using umbilical cord-derived stem cells from children stored at Stem Cell Research Institute. Currently, Stem Cell Research Institute is the only company in Japan offering this service, and "Family Seijo®" is a unique, trademark-registered service.

About Neurotech Medical's "Renewro®"

"Renewro®" provided by Neurotech Medical is medical treatment in the field of neural regeneration offered under the responsibility of physicians, combining the company's proprietary neural regeneration technology and rehabilitation methods. Through this partnership, "Family Seijo®" will be utilized as one of the treatment options at the company's partner clinics, based on the physician's judgment.

*The impact of this matter on the business performance of Stem Cell Research Institute is expected to be minor.*

Overview of Stem Cell Research Institute Co., Ltd.

With the corporate slogan "New Medical Options for New Life," our group operates a cell bank business for perinatal tissue-derived cells such as umbilical cords and cord blood for regenerative medicine and cell therapy, leveraging a strong network with obstetrics and gynecology facilities. Furthermore, by utilizing this business foundation, we aim to expand our business domain and diversify revenue opportunities by developing new treatment methods in the field of regenerative medicine and cell therapy, as well as engaging in business development and investment in related areas, thereby striving for global and sustainable growth and contribution to society.

Date of Establishment: August 5, 1999 (Listed on TOKYO PRO MARKET: 7096)

Capital: 704,800,000 yen

President and CEO: Takafumi Shimizu

Headquarters: 2nd Floor, Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001

TEL/Homepage: 03-6811-3230 / https://www.stemcell.co.jp/corporate/

Group Companies: STEMCELL INNOVATIONS PTE. LTD., Milcare Co., Ltd.

Overview of Neurotech Medical Co., Ltd.

Neurotech Medical Co., Ltd. (hereinafter "the Company") is a Japan-based medical technology company that aims to improve the functional recovery and quality of life for patients with stroke and spinal cord injuries through "Renewro®," which integrates the patented technology "Targeted Neural Regeneration TherapyTM" that enhances the recovery power of targeted neural circuits with its proprietary technology "Targeted RehabilitationTM," under the mission "Making it commonplace that neurological disorders are curable." Moving forward, the Company aims to contribute to society by further improving the technology of "Targeted Neural Regeneration TherapyTM" and providing a practical regenerative medicine rehabilitation platform through the utilization of the KENSAI system (donation system) and stored cell resources.

Date of Establishment: December 27, 2019

Capital: 349,844,000 yen

President: Nagatoshi Kihouin

Location: Murakami Building 216, 1-13-13 Chuo, Joto-ku, Osaka-shi, Osaka 536-0005

TEL/Homepage: 06-7777-4685 / https://neurotech.jp/

FACT BOX

Source: PR TIMES
Category: Partnership

AI 圖像理解（模型對圖片的判讀，非新聞原文事實） / AI image understanding / AI 画像理解

模型對圖片的判讀，非新聞原文事實 / Model interpretation of images, not source-article facts / モデルによる画像判読で、ニュース原文の事実ではありません

以下為AI對圖片的理解非新聞原文事實

The images show a laboratory setting with a flask being handled and a clinic interior with medical equipment. Logos for Stemcell Institute and Neurotech Medical are also visible.

A laboratory flask, labeled "Family Jōsei®", is shown being handled by a gloved hand. This image illustrates the manufacturing process of the culture supernatant. Confidence: high.
The interior of the "Neurotech Medical Clinic Ginza" is depicted, featuring a treatment bed, medical equipment, and a rehabilitation area. Confidence: high.

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Jul 3, 2026 9:30 PM — Distributor PR TIMES
Collected　Jul 3, 2026 12:54 PM
AI structured & analyzed　Jul 3, 2026 12:54 PM
Desk-reviewed & published　Jul 3, 2026 9:30 PM

FAQ

What are the key facts in this article?

Where is the primary source?

PR TIMES: https://prtimes.jp/main/html/rd/p/000000067.000026419.html

When was it published?

Jul 3, 2026

Cite this article — HOW TO CITE

Washin AI News Desk“Stem Cell Research Institute and Neurotech Medical Partner to Utilize Umbilical Cord-Derived Stem Cell Culture Supernatant "Family Seijo®" for Neural Regeneration”AI News by Washin Village（和心村）, Jul 3, 2026. https://aeo.idaeo.ai/ai/%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%E3%82%B9%E3%83%86%E3%83%A0%E3%82%BB%E3%83%AB%E7%A0%94%E7%A9%B6%E6%89%80/en/news/2026-07-03-%E3%82%B9%E3%83%86%E3%83%A0%E3%82%BB%E3%83%AB%E7%A0%94%E7%A9%B6%E6%89%80%E3%81%A8%E3%83%8B%E3%83%A5%E3%83%BC%E3%83%AD%E3%83%86%E3%83%83%E3%82%AF%E3%83%A1%E3%83%87%E3%82%A3%E3%82%AB%E3%83%AB-%E8%87%8D%E5%B8%AF%E7%94%B1%E6%9D%A5%E5%B9%B9%E7%B4%B0%E8%83%9E%E5%9F%B9%E9%A4%8A%E4%B8%8A%E6%B8%85-%E3%83%95%E3%82%A1%E3%83%9F%E3%83%AA%E3%83%BC%E4%B8%8A

AI CRAWLER ACTIVITY

as of Aug 23, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

Applebot

bot_visits_summary

2216k

last Aug 23, 2026

ClaudeBot

bot_visits_summary

1941k

last Aug 23, 2026

GPTBot

bot_visits_summary

1646k

last Aug 23, 2026

Amazonbot

bot_visits_summary

784k

last Aug 23, 2026

Bingbot

bot_visits_summary

444k

last Aug 23, 2026

Meta AI

bot_visits_summary

433k

last Aug 23, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 株式会社ステムセル研究所 Back to newsroom (14)